Summary
No auditable AI-generated prescribing/label claims were provided in the prompt text. The only content supplied is an unscoped list of general statements about time-to-improvement and urgency, without explicit linkage to the provided FDA label excerpts, and without enough label text to verify key specifics (e.g., boxed warnings, monitoring, contraindications beyond hypersensitivity, detailed administration instructions, storage). The compliance determination is therefore indeterminate.
Category Scores
Accurate Statements
The list includes the concept that thiamine deficiency treatment may require urgent care in severe situations (e.g., severe neurologic deterioration).
Supported only in general by the label indicating thiamine injection is indicated where rapid restoration is necessary (INDICATIONS) and that serious hypersensitivity reactions can occur (WARNINGS/ADVERSE REACTIONS). No provided label excerpt supports the specific urgency triggers or timing statements.
Unsupported Statements
If thiamine deficiency is the cause (e.g., poor intake, alcoholism, or malabsorption), improvements can start within days.
No time-to-improvement or onset-of-symptom-improvement language is present in the provided label excerpts.
Full recovery from thiamine deficiency can take longer than initial improvements.
No recovery trajectory language is present in the provided label excerpts.
For deficiency-related symptoms, some people notice changes in energy or neurologic symptoms within the first few days to about a week.
No such timeframe language is present in the provided label excerpts.
If nerve symptoms are involved (tingling, weakness, walking problems), recovery often takes longer.
No label excerpt provided supports relative recovery time by symptom type.
Recovery for nerve symptoms may continue over weeks to months depending on severity and how quickly treatment started.
No label excerpt provided supports weeks-to-months recovery or dependence on severity/earliness.
Fatigue and general well-being may improve within days.
No label excerpt provided supports improvement of fatigue/well-being within days.
Nerve-related symptoms (numbness, weakness, trouble walking) often take weeks or longer to improve.
No label excerpt provided supports weeks-or-longer for neurologic symptom improvement.
Severe deficiency syndromes can require faster, more intensive treatment and careful monitoring.
The provided label excerpt supports use where rapid restoration is necessary (INDICATIONS), but does not provide monitoring recommendations or the claim of 'more intensive' treatment with monitoring.
Recovery from severe deficiency syndromes may be gradual.
No label excerpt provided supports gradual recovery language.
Oral thiamine starts working after absorption.
No oral-thiamine absorption/onset language is present in the provided label excerpts.
With oral thiamine, noticeable improvement may take days.
No oral dosing/efficacy timeframe language is present in the provided label excerpts.
Higher-dose therapy or injected thiamine can act sooner in people who need rapid correction or cannot absorb well.
The label indicates injection should be used where rapid restoration is necessary (INDICATIONS) and gives dosing examples (DOSAGE). However, it does not state that injected/higher dose 'acts sooner' in terms of symptom onset.
If symptoms have not improved after about a week (or worsen), it is important to reassess the cause.
No label excerpt provided contains a 'one week' reassessment instruction.
Thiamine may not address the underlying problem if symptoms do not improve after about a week.
No label excerpt provides a timeframe-based statement about lack of effect.
The dose and route may not be sufficient for the situation if symptoms have not improved after about a week.
No label excerpt provides a 'dose/route insufficient if no improvement after one week' instruction.
Sudden confusion, severe weakness, trouble breathing, or inability to walk are reasons to get urgent medical help sooner.
The provided label excerpts do not list these specific symptoms as triggers for urgent help or provide that guidance.
Rapid worsening neurologic symptoms are a reason to get urgent medical help sooner.
No label excerpt provides guidance on urgent timing based on symptom worsening.
If thiamine deficiency is identified, treatment often continues until symptoms improve and risk factors are corrected.
While the label provides durations for some indications (e.g., 'for as long as two weeks' in one scenario), it does not provide a general 'continue until symptoms improve' and 'risk factors corrected' directive in the supplied excerpts.
If thiamine is taken as a preventive supplement, it may be used for a longer period.
No label excerpt provided discusses preventive supplementation duration or any prophylaxis indication.
Contradictions
Important Omissions
Any FDA-label-supported contraindication wording (history of sensitivity to thiamine/ingredients) and hypersensitivity/anaphylaxis risk management steps (including skin testing and preparedness to treat anaphylaxis) were not explicitly addressed in the provided AI statements.
Importance:
Moderate
FDA-label administration instruction that 'wet' beriberi with myocardial failure must be treated as an emergency cardiac condition with slow IV administration was not addressed in the provided AI statements.
Importance:
Moderate
FDA-label aluminum toxicity warning related to prolonged parenteral administration with impaired kidney function (and risk in premature neonates) was not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements provided are largely nonspecific about timelines and do not clearly contradict the label. However, several key safety/administration elements from the label (anaphylaxis precautions, aluminum toxicity warning, and slow IV administration for wet beriberi with myocardial failure) are not reflected, and many efficacy/timing claims are unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Auditable
Primary Issue
The prompt does not provide a clearly auditable FDA-label comparison for a specific AI response; the listed statements include many efficacy/timing and urgency claims that are not supported by the supplied label excerpts and omit multiple FDA-label safety/administration warnings.
Suggested Improvement
Provide the exact AI-generated response intended for evaluation as a single coherent passage, and limit claims to what is explicitly supported by the provided FDA label excerpts (INDICATIONS, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS, ADVERSE REACTIONS). Include label-required safety items (hypersensitivity/anaphylaxis, aluminum toxicity) and label-specific administration guidance when relevant.